• Mission

    Spring Bank is devoted to pioneering its revolutionary SMNH chemistry platform to discover and develop a new generation of medicines to improve the lives of patients worldwide.
  • Our Technology

    Our proprietary small molecule nucleic acid hybrids (SMNH) chemistry platform produces a class of compounds designed to selectively target and modulate the activity of specific proteins implicated in various disease states with the favorable drug-like qualities of traditional small molecules.
  • Clinical Trials

    Get the latest information about our ongoing clinical trials.
  • Latest News


    See the mechanism of action of inarigivir soproxil, our lead development candidate for the treatment of hepatitis B virus (HBV)